Medicamen Biotech's Q1 FY 2025-26 Quarterly Results

Result Summary

• Medicamen Biotech Ltd reported a 9.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 0.3%.
• Its expenses for the quarter were down by 8.5% QoQ and 1.7% YoY.
• The net profit decreased 21.6% QoQ and increased 100.0% YoY.
• The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.2 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Medicamen Biotech Ltd is a pharmaceutical company primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company's product portfolio includes a wide range of generic drugs, catering to various therapeutic segments. Medicamen Biotech operates within the pharmaceutical industry, which is characterized by innovation, regulatory oversight, and a focus on research and development. As of the latest available information, specific recent developments regarding the company are not provided in the financial data. However, companies in this sector typically focus on expanding their product lines and enhancing production capacities to meet market demand.

Revenue

For the first quarter of fiscal year 2026 (Q1FY26), Medicamen Biotech Ltd recorded a total income of ₹43.52 crores. This represents a 9.1% decrease from the previous quarter (Q4FY25), where total income was ₹47.89 crores. Compared to the same quarter in the previous year (Q1FY25), where total income was ₹43.63 crores, there is a slight decrease of 0.3%. These figures reflect the company's revenue-generating activities within the reporting period, providing insight into its sales performance over the specified quarters.

Profitability

In Q1FY26, Medicamen Biotech Ltd achieved a profit before tax of ₹2.13 crores, which is a 19.9% decline from ₹2.66 crores in Q4FY25. However, compared to Q1FY25, where the profit before tax was ₹1.56 crores, there is a noticeable increase of 36.5%. After accounting for taxes amounting to ₹0.53 crores, the profit after tax for Q1FY26 stood at ₹1.60 crores. This represents a 21.6% decrease from the previous quarter's figure of ₹2.04 crores but shows a substantial year-over-year increase of 100% from ₹0.80 crores in Q1FY25. The earnings per share for Q1FY26 was ₹1.20, down 25% from ₹1.60 in Q4FY25 but doubling from ₹0.60 in Q1FY25.

Operating Metrics

During Q1FY26, Medicamen Biotech Ltd reported total expenses of ₹41.38 crores, reflecting an 8.5% decrease from ₹45.23 crores recorded in Q4FY25. When compared to Q1FY25, where total expenses were ₹42.08 crores, there is a reduction of 1.7%. The company's tax expense for Q1FY26 was ₹0.53 crores, which is a 14.5% decrease from the previous quarter's tax expense of ₹0.62 crores. Year-over-year, the tax expense decreased by 30.3% from ₹0.76 crores in Q1FY25. These operating metrics highlight the company's cost management strategies and tax obligations during the reported period.